Like most of you, I don’t like to lose money. So you might be wondering why I was so quick to scoop up more shares of Gilead Sciences (NASDAQ:GILD) stock after its latest earnings report. After all, management shared a forecast for 2017 hepatitis C antiviral sales 39% lower than 2016 figures, and that’s at the high end of the provided range.
Before you assume I’ve completely....More>>>
Last year, Gilead Sciences (NASDAQ:GILD) managed a feat that very few of its peers ever have (or probably ever will): It shed a staggering $40 billion in value without a single top-selling drug going off patent.
GILD Market Cap data by YCharts.
In fact, the biotech actually launched multiple new products last year, such as the HIV medsOdefsey and Descovy, along with the latest addition....More>>>
William Patalon III
In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.
The announcement caught my eye for several reasons…
This is premium content for Private Briefing subscribers only.
On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):
Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although....More>>>
On Monday, energy stocks soared, pushing the Dow Jones Industrial Average to within almost 180 points of the 20,000 mark. But declines in the financials offset the energy gains and left the industrials short of the mark despite a gain of 0.2% for the Dow.
The S&P 500 fell 0.1%, and the Nasdaq lost 0.6% due to a decline in the financial sector of 0.9% after five sessions in the black.....More>>>
Best Biotech ETF: The biotech sector has been greatly outperforming the broader markets over the past three months. In fact, the Nasdaq Biotechnology sector has climbed more than 14% since June, while the Dow is up just 2% in that time.
And we see those biotech gains continuing from here. That’s why we’re bringing readers the best biotech ETF to buy now.
ImmunoGen (NASDAQ:IMGN) is up 21.8% at 1:06 p.m. EST on no apparent news. Of course, it’s a biotech, so that’s often par for the course.
One possibility is that day traders are just doing their thing, following the momentum, which pushes the stock price higher. We’ll know in a few days if the share price returns to previous levels.
Stocks traded higher today day in a week that is known for producing pretty solid returns.
The S&P 500 rose 0.2% to 2,268.88 today, while the Dow Jones Industrial Average advanced11.23 points, or 0.1%, to 19,945.04. The Nasdaq Composite gained 0.5% to 5,487.44.
Rhino Trading’s Michael Block argues that what’s working will continue working....More>>>
Wednesday was a strong day for the stock market, as the Dow finished up nearly 100 points and the S&P 500 and Nasdaq both posted gains as well. Investors remained generally upbeat about the prospects for the U.S. economy in 2017, and a rise in crude oil prices helped lift the energy sector higher during the market session. Yet comments during a press conference from President-elect Donald Trump....More>>>
Strong minds discuss ideas, average minds discuss events, weak minds discuss people.” – Socrates
I received an inquiry from a real-time follower yesterday around an “off the radar” concern that rarely comes up in conversation but it is a name I own a few shares in. Given it is selling right at the same level as it was when I did an exclusive “first look”....More>>>